ClinicalTrials.gg
CompletedNCT02348619OSAUpdated Sep 9, 2019Results posted

"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"

A Phase 3 interventional study of JZP-110 in Obstructive Sleep Apnea, sponsored by Jazz Pharmaceuticals. Completed at 30 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-09.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 753 studies in Sleep Apnea, Obstructive with a site in United States — 126 open to participants now, 160 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.

Enrollment
99th of 594
174 · median 49
Started
2015
with 42 others
Phase 3
39 of 753
6 open now
Registered
290th of 753
by date

Among the 753 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 99th largest by enrollment of the 594 interventional ones that give a count, is one of 43 that started in 2015, is one of 39 in phase 3, and was the 290th registered.

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

126 of the 753 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 753 studies in Sleep Apnea, Obstructive with a site in United States, or all of them as a file.
02

Study summary

This trial is a 6-week, double-blind, placebo-controlled, randomized-withdrawal, multicenter study of safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with OSA.

03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  1. Male or female between 18 and 75 years of age, inclusive
  2. Diagnosis of OSA according to ICSD-3 criteria
  3. from 18 to \<45 kg/m2
  4. Consent to use a medically acceptable method of
  5. Willing and able to provide written

Major Exclusion Criteria:

  1. Female subjects who are pregnant, nursing, or lactating.
  2. Any other medical, behavioral, or psychiatric disorder other than OSA that is associated with excessive sleepiness
  3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to criteria
  4. History or presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy or safety assessments or the ability of the subject to complete the trial per the judgment of the principal investigator
  5. History of bariatric surgery within the past year or a history of any gastric bypass procedure
  6. Presence or history of significant cardiovascular disease
  7. Use of any over the counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness
  8. Received an drug in the past 30 days or five half-lives (whichever is longer)
  9. Previous exposure to or participation in a clinical trial of JZP-110 (ADX-N05, R228060, or YKP10A)
  10. History of phenylketonuria (PKU) or history of to phenylalanine-derived products
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
174 participants (actual)

Study arms

  • Active comparator
    75, 150, 300 mg of JZP-110

    Once Daily Dosing

    Drug: JZP-110

  • Active comparator
    Placebo

    Once Daily Dosing

    Drug: JZP-110

Interventions

06

What researchers measure

Primary outcomes

  1. Change in the Maintenance of Wakefulness Test (MWT)

    Change in the mean sleep latency time as determined from the first four trials of a 40-minute MWT from the end of the Stable Dose Phase to the end of the Double-blind Withdrawal Phase. Mean sleep latency defined as the average of the first four MWT trial's measurements.

    Time frame: Week 4 to Week 6

  2. Change in the Epworth Sleepiness Scale (ESS)

    Change in Epworth Sleepiness Scale (ESS) score from the end of the Stable Dose Phase to the end of the Double-blind Withdrawal Phase. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from week 4 to week 6.

    Time frame: Week 4 to Week 6

Secondary outcomes

  1. Patient Global Impression of Change (PGIc)

    Percentage of subjects reported as worse (minimally, much, or very much) on the PGIc at the end of the Double-blind Withdrawal Phase. PGIc was rated by subjects and measures the change in their condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.

    Time frame: Week 4 to Week 6

  2. Clinical Global Impression of Change (CGIc)

    Percentage of subjects reported as worse (minimally, much, or very much) on the CGIc at the end of the Double-blind Withdrawal Phase. CGIc was rated by clinicians and measures the change in the subject's condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.

    Time frame: Week 4 to Week 6

  3. Change in Functional Outcomes of Sleep Questionnaire (FOSQ-10)

    Change is total score from the end of the stable dose phase to the end of the double blind withdrawal phase. Functional Outcomes of Sleep Questionnaire Short Version (FOSQ-10) is a 10-item disease-specific quality of life questionnaire to assess the effect of excessiveness sleepiness on multiple activities of everyday living. The FOSQ-10 consists of 10 questions, each scored on a scale from 1-4. The questionnaire has a 4-point response format for each question (1 = extreme difficulty, 2 = moderate difficulty, 3 = a little difficulty, and 4 = no difficulty). The total score is derived by the mean of the 5 subscale scores, multiplied by 5, resulting in a possible range of scores between 5 to 20; lower FOSQ-10 scores are worse, indicating more difficulty carrying out activities; higher FOSQ-10 scores are better, indicating less difficulty carrying out activities.

    Time frame: Week 4 to Week 6

07

Results

Posted Sep 9, 2019

Participant flow

Titration Phase
Participant flow — Titration Phase
MilestoneJZP-110Placebo
Started1740
Completed1570
Not completed170
Stable-Dose Phase
Participant flow — Stable-Dose Phase
MilestoneJZP-110Placebo
Started1570
Completed1240
Not completed330
Double-Blind Withdrawal Phase
Participant flow — Double-Blind Withdrawal Phase
MilestoneJZP-110Placebo
Started6262
Completed6062
Not completed20

Outcome measures

PrimaryChange in the Maintenance of Wakefulness Test (MWT)

Change in the mean sleep latency time as determined from the first four trials of a 40-minute MWT from the end of the Stable Dose Phase to the end of the Double-blind Withdrawal Phase. Mean sleep latency defined as the average of the first four MWT trial's measurements.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · minutes
Change in the Maintenance of Wakefulness Test (MWT)
minutesJZP-110Placebo
Change in the Maintenance of Wakefulness Test (MWT)-0.96 ± 1.350-12.11 ± 1.326
PrimaryChange in the Epworth Sleepiness Scale (ESS)

Change in Epworth Sleepiness Scale (ESS) score from the end of the Stable Dose Phase to the end of the Double-blind Withdrawal Phase. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from week 4 to week 6.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · points on a scale
Change in the Epworth Sleepiness Scale (ESS)
points on a scaleJZP-110Placebo
Change in the Epworth Sleepiness Scale (ESS)-0.1 ± 0.734.5 ± 0.71
SecondaryPatient Global Impression of Change (PGIc)

Percentage of subjects reported as worse (minimally, much, or very much) on the PGIc at the end of the Double-blind Withdrawal Phase. PGIc was rated by subjects and measures the change in their condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.

Time frame:
Week 4 to Week 6
Reported as:
Number · percentage of subjects
Patient Global Impression of Change (PGIc)
percentage of subjectsJZP-110Placebo
Patient Global Impression of Change (PGIc)2050
SecondaryClinical Global Impression of Change (CGIc)

Percentage of subjects reported as worse (minimally, much, or very much) on the CGIc at the end of the Double-blind Withdrawal Phase. CGIc was rated by clinicians and measures the change in the subject's condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.

Time frame:
Week 4 to Week 6
Reported as:
Number · percentage of subjects
Clinical Global Impression of Change (CGIc)
percentage of subjectsJZP-110Placebo
Clinical Global Impression of Change (CGIc)2259
SecondaryChange in Functional Outcomes of Sleep Questionnaire (FOSQ-10)

Change is total score from the end of the stable dose phase to the end of the double blind withdrawal phase. Functional Outcomes of Sleep Questionnaire Short Version (FOSQ-10) is a 10-item disease-specific quality of life questionnaire to assess the effect of excessiveness sleepiness on multiple activities of everyday living. The FOSQ-10 consists of 10 questions, each scored on a scale from 1-4. The questionnaire has a 4-point response format for each question (1 = extreme difficulty, 2 = moderate difficulty, 3 = a little difficulty, and 4 = no difficulty). The total score is derived by the mean of the 5 subscale scores, multiplied by 5, resulting in a possible range of scores between 5 to 20; lower FOSQ-10 scores are worse, indicating more difficulty carrying out activities; higher FOSQ-10 scores are better, indicating less difficulty carrying out activities.

Time frame:
Week 4 to Week 6
Reported as:
Least squares mean · units on a scale
Change in Functional Outcomes of Sleep Questionnaire (FOSQ-10)
units on a scaleJZP-110Placebo
Change in Functional Outcomes of Sleep Questionnaire (FOSQ-10)-0.15 ± 0.393-1.31 ± 0.381

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
JZP-110 (Entire Study)0/174 (0%)0/174 (0%)58/174 (33.3%)
Placebo (Randomized Withdrawal)0/62 (0%)0/62 (0%)0/62 (0%)
Most frequent other events
Most frequent other events
EventJZP-110 (Entire Study)Placebo (Randomized Withdrawal)
HeadacheNervous system disorders20/1740/62
DizzinessNervous system disorders14/1740/62
Dry mouthGastrointestinal disorders13/1740/62
NauseaGastrointestinal disorders13/1740/62
InsomniaPsychiatric disorders11/1740/62
PalpitationsCardiac disorders9/1740/62

Baseline characteristics

Age, Continuous
Age, Continuous(years)Double-Blind Withdrawal Phase
Placebo56.2 ± 9.75
JZP-11056.3 ± 11.36
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Withdrawal Phase
Placebo — Female21
Placebo — Male41
JZP-110 — Female26
JZP-110 — Male36
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double-Blind Withdrawal Phase
Placebo — American Indian or Alaska Native0
Placebo — Asian2
Placebo — Native Hawaiian or Other Pacific Islander0
Placebo — Black or African American15
Placebo — White45
Placebo — More than one race0
Placebo — Unknown or Not Reported0
JZP-110 — American Indian or Alaska Native0
JZP-110 — Asian0
JZP-110 — Native Hawaiian or Other Pacific Islander0
JZP-110 — Black or African American12
JZP-110 — White50
JZP-110 — More than one race0
JZP-110 — Unknown or Not Reported0
08

Study locations

30 sites
  • Sleep Disorder Center of Alabama
    Birmingham, Alabama 35213, United States
  • The Research Center of Southern California
    Oceanside, California 92056, United States
  • SDS Clinical Trials, INC
    Orange, California 92868, United States
  • Santa Monica Clinical Trials
    Santa Monica, California 90404, United States
  • Critical Care Pulmonary & Sleep Associates, LLC
    Lakewood, Colorado 80228, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • Broward Research Group, Inc.
    Hollywood, Florida 33024, United States
  • Oviedo Medical Research, LLC
    Oviedo, Florida 32765, United States
  • Emory Sleep Center
    Atlanta, Georgia 30329, United States
  • Rowe Neurology Institute RNI - Lenexa
    Lenexa, Kansas 66214, United States
  • Veritas Clinical Specialities LTD
    Topeka, Kansas 66606, United States
  • Advanced Neurodiagnostic Ceneter
    Metairie, Louisiana 70006, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21224, United States
  • Brigham & Womens Hospital
    Boston, Massachusetts 02115, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Center for Sleep & Circadian Neurobiology
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Sleep Medicine Center
    Pittsburgh, Pennsylvania 15213, United States
  • Lowcountry Lung Critical Care
    Charleston, South Carolina 29406, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • EVMS Sleep Medicine
    Norfolk, Virginia 23510, United States
  • American Sleep Medicine
    Vienna, Virginia 22182, United States
  • Tampere University Hospital
    Tampere, Södra Finlands Län 33200, Finland
  • Turku University Hospital, Sleep Clinic
    Turku, Västra Finlands Län 20520, Finland
  • Helsinki Sleep Center
    Helsinki, 00420, Finland
  • Grenoble University Hospital
    La Tronche, Rhône-Alpes 38700, France
  • CHU de Poitiers
    Poitiers, Vienne 86000, France
  • Klinische Forschung Schwerin GmbH
    Schwerin, Mecklenburg-Vorpommern 19055, Germany
  • Somnolab Dortmund
    Dortmund, Nordrhein-Westfalen 44263, Germany
  • Department of Sleep Medicine
    Gӧteborg, Västra Götalands Län SE 413 45, Sweden
09

References and documents

Publications

  • Strollo PJ Jr, Hedner J, Collop N, Lorch DG Jr, Chen D, Carter LP, Lu Y, Lee L, Black J, Pepin JL, Redline S; Tones 4 Study Investigators. Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study. Chest. 2019 Feb;155(2):364-374. doi: 10.1016/j.chest.2018.11.005. Epub 2018 Nov 22. PubMed 30471270 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2019, 2 years 10 months after primary completion. A results delay was requested in Nov 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2015
First posted
Jan 28, 2015
Start
May 2015
Primary completionActual
Nov 2016
CompletionActual
Nov 2016
Results delay requested
Nov 16, 2017
Results first posted
Sep 9, 2019
Last update
Sep 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02348619
Responsible party
Sponsor
First posted
Jan 28, 2015
Start date
May 2015
Primary completion
Nov 2016
Completion
Nov 2016
Results posted
Sep 9, 2019
Last update
Sep 9, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion